CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients

Pharmacopsychiatry

Volumn 36, Issue 2, 2003, Pages 73-78

  Lohmann, P L ^a   Bagli, M ^a   Krauss, H ^c   Muller D J ^a   Schulze, T G ^a   Fangerau, H ^a   Ludwig, M ^a   Barkow, K ^a   Held, T ^b   Heun, R ^a   Maier, W ^a   Rietschel, M ^a   Rao, Marie Luise ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Mental State Hospital   (Germany)

^c Psychiatric Department of the Christian General Hospital Quakenbrück   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENPERIDOL; BROMPERIDOL; CHLORPROTHIXENE; CLOZAPINE; CYTOCHROME P450 2D6; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; PERAZINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PROMETHAZINE; PROTHIPENDYL; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZOTEPINE; ZUCLOPENTHIXOL;

ADULT; AEROBIC METABOLISM; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG METABOLISM; ENZYME SUBSTRATE; FEMALE; GENE DUPLICATION; GENE FUNCTION; GENOTYPE; HEREDITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEX DIFFERENCE; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DYSKINESIA, DRUG-INDUCED; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 0038293338     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39048     Document Type: Article

References (54)

1. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl.) 1997; 131: 174-179
2. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997; 170: 23-26
3. Arthur H, Dahl ML, Siwers B, Sjöqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995; 15: 211-216
4. Broly F, Marez D, Sabbagh N, Legrand M, Millecamps S, LoGuidince JM, Boone P, Meyer UA. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 1995; 5: 373-384
5. Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996; 18: 393-396
6. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995: 10 Suppl 3: 105-114
7. Casey DE. Tardive Dyskinesia: Pathophysiology. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The Fourth Generation of Progress New York: Raven Press, 1995: p. 1497-1511
8. Cichon S, Nöthen MM, Rietschel M, Propping P. Pharmacogenetics of schizophrenia. Am J Med Genet 2000; 97: 98-106
9. Coutts RT, Urichuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry. Cell Mol Neurobiol 1999; 19: 325-354
10. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993; 3: 61-70
11. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201
12. Daniels J, Williams J, Asherson P, McGuffin P, Owen M. No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-bydroxylase (CYP2D6) and the dopamine transporter (DAT). Am J Med Genet 1995; 60: 85-87
13. Dawson E, Powell JF, Nöthen MM, Crocq MA, Lanczik M, Korner J et al. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia. Psychiatr Genet 1994; 4: 215-218
14. DeVane CL. Principles of pharmacokinetics and pharmacodynamics. In Schatzberg AF, Nemeroff CB, editors. Textbook of Psychopharmacology; 2d ed New York, NY: APA Press, 1998: 155-169
15. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990; 46: 377-394
16. Ellingrod VL, Schultz SK, Arndt S. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr Genet 2000; 10: 9-11
17. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35: 837-844
18. Fang J, Zuo D, Yu PH. Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology (Berl) 1995; 121: 373-378
19. Fang J, Baker GB, Silverstone PH, Coutts RT. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 1997; 17: 227-233
20. Glavac D, Dean M. Optimization of the single-strand conformation polymorphism (SSCP) technique for detection of point mutations. Hum Mutat 1993; 2: 404-414
21. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. J Clin Psychiatry 1993; 54: 133-139
22. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15-26
23. Held T, Weber H, Krauss H, Ahle G, Hager B, Alfter D et al. Clinical characteristics of patients with tardive dyskinesias. Fortschr Neurol Psychiatr 2000; 68: 321-331
24. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 2001; 482: 11-19
25. Iwahashi K. CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biol Psychiatry 1994; 36: 781-782
26. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993; 19: 303-315
27. Jonsson EG, Dahl ML, Roh HK, Jerling M, Sedvall GC. Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphism and schizophrenia. Psychiatr Genet 1998; 8: 25-28
28. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989; 50: 322-328
29. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998; 32: 101-106
30. Kawanishi C, Shimoda Y, Fujimaki J, Onishi H, Suzuki K, Hanihara T et al. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome. J Neuro Sci 1998; 160: 102-104
31. Kawanishi C, Hanihara T, Maruyama Y, Matsumura T, Onishi H, Inoue K et al. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B. Psychiatr Genet 1997; 7: 127-129
32. Kroemer HK, Eichelbaum M. "It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995; 56: 2285-2298
33. Labbé L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J, Hamelin BA. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000; 10: 425-438
34. Løvlie R, Daly AK, Molven A, Idle JR, Steen VM. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS 1996; 392: 30-34
35. Løvlie R, Daly AK, Blennerhassett R, Ferrier N, Steen VM. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. Int J Neuropsychopharmacol 2000; 3: 1-65
36. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584-586
37. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269-296
38. Morgan ET, Sewer MB, Iber H, Gonzalez FJ, Lee YH, Tukey RH et al. Physiological and pathophysiological regulation of cytochrome P450. Drug Metab Dispos 1998; 26: 1232-1240
39. Niznik HB, Tyndale RF, Sallee FR, Gonzalez FJ, Hardwick JP, Inaba T, Kalow W. The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch Biochem Biophys 1990; 276: 424-432
40. Rietschel M, Krauss H, Müller DJ, Schulze TG, Knapp M, Marwinski K et al. Dopamine D3 receptor variant and tardive dyskinesia. Eur Arch Psychiatry Clin Neurosci 2000; 250: 31-35
41. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-295
42. Sachse C, Brockmöller J, Hildebrand M, Muller K, Roots I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 1998; 8: 181-185
43. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487
44. Schulze TG, Schumacher J, Müller DJ, Krauss H, Alfter D, Maroldt A et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105: 498-501
45. Scordo MG, Spina E, Romeo P, Dahl ML, Bertilsson L, Johansson I, Sjöqvist F. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 2000; 56: 679-683
46. Simpson GM, Lee JH, Zoubok B, Gardos G. A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 1979; 64: 171-179
47. Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980; 37: 1368-1373
48. Spina E, Sturiale V, Valvo S, Ancione M, Di Rosa AE, Meduri M, Caputi AP. Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. Acta Psychiatr Scand 1992; 86: 364-366
49. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994; 46 Suppl 1: 417-424
50. Vandel P, Haffen E, Vandel S, Bonin B, Nezelof S, Sechter D et al. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol 1999; 55: 659-665
51. Vandel P, Haffen E, Vandel S, Bonin B, Sechter D, Bizouard P, Dalery J. Drug extrapyramidal side-effects or not: is there a dextromethorphan phenotype difference? Therapie 2000; 55: 349-353
52. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC et al. Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 2000; 855: 235-243
53. Woerner MG, Alvir JMJ, Saltz BL, Liebermann JA, Kane JM. Prospecive study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155: 1521-1528
54. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992; 18: 701-715